p62/SQSTM1—Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer

FEBS Letters

Volumn , Issue , 2016, Pages 2375-2397

  Taniguchi, Koji ^a,b,c   Yamachika, Shinichiro ^a   He, Feng ^a   Karin, Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

autophagy; HCC; mTORC1; NASH; NF B; NRF2; p62 SQSTM1

Indexed keywords

B RAF KINASE; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BRCA1 PROTEIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; ELAV LIKE PROTEIN 2; FARNESOID X RECEPTOR; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; K RAS PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; NERVE GROWTH FACTOR; NOTCH RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; PEROXIREDOXIN 1; PROTEIN KINASE C; PROTEIN P62; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEQUESTOSOME 1; SORAFENIB; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NRF2; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ANTIOXIDANT RESPONSIVE ELEMENT; APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; BINDING AFFINITY; CELL AGING; CELL DEATH; ENDOPLASMIC RETICULUM STRESS; GLUCOSE METABOLISM; HUMAN; LIVER ADENOMA; LIVER CANCER; LIVER CELL CARCINOMA; LIVER REGENERATION; MALLORY BODY; METABOLIC REGULATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UBIQUITINATION;

EID: 84981711313     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1002/1873-3468.12301     Document Type: Review

References (330)

1. Park I, Chung J, Walsh CT, Yun Y, Strominger JL and Shin J (1995) Phosphotyrosine-independent binding of a 62-kDa protein to the src homology 2 (SH2) domain of p56lck and its regulation by phosphorylation of Ser-59 in the lck unique N-terminal region. Proc Natl Acad Sci USA 92, 12338–12342.
2. Okazaki M, Ito S, Kawakita K, Takeshita S, Kawai S, Makishima F, Oda H and Kakinuma A (1999) Cloning, expression profile, and genomic organization of the mouse STAP/A170 gene. Genomics 60, 87–95.
3. Ishii T, Yanagawa T, Kawane T, Yuki K, Seita J, Yoshida H and Bannai S (1996) Murine peritoneal macrophages induce a novel 60-kDa protein with structural similarity to a tyrosine kinase p56lck-associated protein in response to oxidative stress. Biochem Biophys Res Commun 226, 456–460.
4. Puls A, Schmidt S, Grawe F and Stabel S (1997) Interaction of protein kinase C zeta with ZIP, a novel protein kinase C-binding protein. Proc Natl Acad Sci USA 94, 6191–6196.
5. Sanchez P, De Carcer G, Sandoval IV, Moscat J and Diaz-Meco MT (1998) Localization of atypical protein kinase C isoforms into lysosome-targeted endosomes through interaction with p62. Mol Cell Biol 18, 3069–3080.
6. Lamark T, Perander M, Outzen H, Kristiansen K, Øvervatn A, Michaelsen E, Bjørkøy G and Johansen T (2003) Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins. J Biol Chem 278, 34568–34581.
7. Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT and Moscat J (1999) The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J 18, 3044–3053.
8. Sanz L, Diaz-Meco MT, Nakano H and Moscat J (2000) The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J 19, 1576–1586.
9. Bjorkoy G, Lamark T, Brech A, Outzen H, Perander M, Overvatn A, Stenmark H and Johansen T (2005) p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J Cell Biol 171, 603–614.
10. Komatsu M, Kurokawa H, Waguri S, Taguchi K, Kobayashi A, Ichimura Y, Sou YS, Ueno I, Sakamoto A, Tong KI et al. (2010) The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat Cell Biol 12, 213–223.
11. Vadlamudi RK, Joung I, Strominger JL and Shin J (1996) p62, a phosphotyrosine-independent ligand of the SH2 domain of p56lck, belongs to a new class of ubiquitin-binding proteins. J Biol Chem 271, 20235–20237.
12. Moscat J and Diaz-Meco MT (2012) p62: a versatile multitasker takes on cancer. Trends Biochem Sci 37, 230–236.
13. Komatsu M, Kageyama S and Ichimura Y (2012) p62/SQSTM1/A170: physiology and pathology. Pharmacol Res 66, 457–462.
14. Manley S, Williams JA and Ding WX (2013) Role of p62/SQSTM1 in liver physiology and pathogenesis. Exp Biol Med (Maywood) 238, 525–538.
15. Katsuragi Y, Ichimura Y and Komatsu M (2015) p62/SQSTM1 functions as a signaling hub and an autophagy adaptor. FEBS J 282, 4672–4678.
16. Rodriguez A, Durán A, Selloum M, Champy MF, Diez-Guerra FJ, Flores JM, Serrano M, Auwerx J, Diaz-Meco MT and Moscat J (2006) Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab 3, 211–222.
17. Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Porollo A, Hansen M, Moscat J and Diaz-Meco MT (2011) p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol Cell 44, 134–146.
18. Copple IM, Lister A, Obeng AD, Kitteringham NR, Jenkins RE, Layfield R, Foster BJ, Goldring CE and Park BK (2010) Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway. J Biol Chem 285, 16782–16788.
19. Lau A, Wang XJ, Zhao F, Villeneuve NF, Wu T, Jiang T, Sun Z, White E and Zhang DD (2010) A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol 30, 3275–3285.
20. Jain A, Lamark T, Sjøttem E, Larsen KB, Awuh JA, Øvervatn A, McMahon M, Hayes JD and Johansen T (2010) p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem 285, 22576–22591.
21. Riley BE, Kaiser SE, Shaler TA, Ng AC, Hara T, Hipp MS, Lage K, Xavier RJ, Ryu KY, Taguchi K et al. (2010) Ubiquitin accumulation in autophagy-deficient mice is dependent on the Nrf2-mediated stress response pathway: a potential role for protein aggregation in autophagic substrate selection. J Cell Biol 191, 537–552.
22. Pankiv S, Clausen TH, Lamark T, Brech A, Bruun JA, Outzen H, Øvervatn A, Bjørkøy G and Johansen T (2007) p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem 282, 24131–24145.
23. Komatsu M, Waguri S, Koike M, Sou YS, Ueno T, Hara T, Mizushima N, Iwata J, Ezaki J, Murata S et al. (2007) Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131, 1149–1163.
24. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR and Ashkenazi A (2009) Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137, 721–735.
25. Laurin N, Brown JP, Morissette J and Raymond V (2002) Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 70, 1582–1588.
26. Hocking LJ, Lucas GJ, Daroszewska A, Mangion J, Olavesen M, Cundy T, Nicholson GC, Ward L, Bennett ST, Wuyts W et al. (2002) Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet 11, 2735–2739.
27. Zhang J, Yang Z and Dong J (2016) P62: an emerging oncotarget for osteolytic metastasis. J Bone Oncol 5, 30–37.
28. Rea SL, Walsh JP, Layfield R, Ratajczak T and Xu J (2013) New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget's disease of bone. Endocr Rev 34, 501–524.
29. Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C et al. (2009) Autophagy suppresses tumorigenesis through elimination of p62. Cell 137, 1062–1075.
30. Joung I, Strominger JL and Shin J (1996) Molecular cloning of a phosphotyrosine-independent ligand of the p56lck SH2 domain. Proc Natl Acad Sci USA 93, 5991–5995.
31. Pankiv S, Lamark T, Bruun JA, Øvervatn A, Bjørkøy G and Johansen T (2010) Nucleocytoplasmic shuttling of p62/SQSTM1 and its role in recruitment of nuclear polyubiquitinated proteins to promyelocytic leukemia bodies. J Biol Chem 285, 5941–5953.
32. Bao L, Chandra PK, Moroz K, Zhang X, Thung SN, Wu T and Dash S (2014) Impaired autophagy response in human hepatocellular carcinoma. Exp Mol Pathol 96, 149–154.
33. Inami Y, Waguri S, Sakamoto A, Kouno T, Nakada K, Hino O, Watanabe S, Ando J, Iwadate M and Yamamoto M (2011) Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells. J Cell Biol 193, 275–284.
34. Umemura A, He F, Taniguchi K, Nakagawa H, Yamachika S, Font-Burgada J, Zhong Z, Subramaniam S, Raghunandan S, Duran A et al. (2016) p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell 29, 935–948.
35. Jin GZ, Dong H, Yu WL, Li Y, Lu XY, Yu H, Xian ZH, Dong W, Liu YK, Cong WM et al. (2013) A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values. BMC Cancer 13, 161.
36. Shimizu T, Inoue KI, Hachiya H, Shibuya N, Aoki T and Kubota K (2016) Accumulation of phosphorylated p62 is associated with NF-E2-related factor 2 activation in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci, doi: 10.1002/jhbp.364.
37. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A and Denk H (2002) p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160, 255–263.
38. Saito T, Ichimura Y, Taguchi K, Suzuki T, Mizushima T, Takagi K, Hirose Y, Nagahashi M, Iso T, Fukutomi T et al. (2016) p62/Sqstm1 promotes malignancy of HCV-positive hepatocellular carcinoma through Nrf2-dependent metabolic reprogramming. Nat Commun 7, 12030.
39. Aishima S, Fujita N, Mano Y, Iguchi T, Taketomi A, Maehara Y, Oda Y and Tsuneyoshi M (2010) p62+ Hyaline inclusions in intrahepatic cholangiocarcinoma associated with viral hepatitis or alcoholic liver disease. Am J Clin Pathol 134, 457–465.
40. Mohamed A, Ayman A, Deniece J, Wang T, Kovach C, Siddiqui MT and Cohen C (2015) P62/ubiquitin IHC expression correlated with clinicopathologic parameters and outcome in gastrointestinal carcinomas. Front Oncol 5, 70.
41. Inoue D, Suzuki T, Mitsuishi Y, Miki Y, Suzuki S, Sugawara S, Watanabe M, Sakurada A, Endo C, Uruno A et al. (2012) Accumulation of p62/SQSTM1 is associated with poor prognosis in patients with lung adenocarcinoma. Cancer Sci 103, 760–766.
42. Schlafli AM, Adams O, Galván JA, Gugger M, Savic S, Bubendorf L, Schmid RA, Becker KF, Tschan MP, Langer R et al. (2016) Prognostic value of the autophagy markers LC3 and p62/SQSTM1 in early-stage non-small cell lung cancer. Oncotarget, doi: 10.18632/oncotarget.9647.
43. Kuo WL, Sharifi MN, Lingen MW, Ahmed O, Liu J, Nagilla M, Macleod KF and Cohen EE (2014) p62/SQSTM1 accumulation in squamous cell carcinoma of head and neck predicts sensitivity to phosphatidylinositol 3-kinase pathway inhibitors. PLoS One 9, e90171.
44. Inui T, Chano T, Takikita-Suzuki M, Nishikawa M, Yamamoto G and Okabe H (2013) Association of p62/SQSTM1 excess and oral carcinogenesis. PLoS One 8, e74398.
45. Adams O, Dislich B, Berezowska S, Schläfli AM, Seiler CA, Kroell D, Tschan MP and Langer R (2016) Prognostic relevance of autophagy markers LC3B and p62 in esophageal adenocarcinomas. Oncotarget, doi: 10.18632/oncotarget.9649.
46. Masuda GO, Yashiro M, Kitayama K, Miki Y, Kasashima H, Kinoshita H, Morisaki T, Fukuoka T, Hasegawa T, Sakurai K et al. (2016) Clinicopathological correlations of autophagy-related proteins LC3, Beclin 1 and p62 in gastric cancer. Anticancer Res 36, 129–136.
47. Park JM, Huang S, Wu TT, Foster NR and Sinicrope FA (2013) Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther 14, 100–107.
48. Thompson HG, Harris JW, Wold BJ, Lin F and Brody JP (2003) p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. Oncogene 22, 2322–2333.
49. Luo RZ, Yuan ZY, Li M, Xi SY, Fu J and He J (2013) Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. Onco Targets Ther 6, 883–888.
50. Rolland P, Madjd Z, Durrant L, Ellis IO, Layfield R and Spendlove I (2007) The ubiquitin-binding protein p62 is expressed in breast cancers showing features of aggressive disease. Endocr Relat Cancer 14, 73–80.
51. Choi J, Jung W and Koo JS (2013) Expression of autophagy-related markers beclin-1, light chain 3A, light chain 3B and p62 according to the molecular subtype of breast cancer. Histopathology 62, 275–286.
52. Kitamura H, Torigoe T, Asanuma H, Hisasue SI, Suzuki K, Tsukamoto T, Satoh M and Sato N (2006) Cytosolic overexpression of p62 sequestosome 1 in neoplastic prostate tissue. Histopathology 48, 157–161.
53. Giatromanolaki A, Sivridis E, Mendrinos S, Koutsopoulos AV and Koukourakis MI (2014) Autophagy proteins in prostate cancer: relation with anaerobic metabolism and Gleason score. Urol Oncol 32, 39. e11–8.
54. Ellis RA, Horswell S, Ness T, Lumsdon J, Tooze SA, Kirkham N, Armstrong JL and Lovat PE (2014) Prognostic impact of p62 expression in cutaneous malignant melanoma. J Invest Dermatol 134, 1476–1478.
55. Iwadate R, Inoue J, Tsuda H, Takano M, Furuya K, Hirasawa A, Aoki D and Inazawa J (2015) High expression of p62 protein is associated with poor prognosis and aggressive phenotypes in endometrial cancer. Am J Pathol 185, 2523–2533.
56. Ju LL, Zhao CY, Ye KF, Yang H and Zhang J (2016) Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues. Eur Rev Med Pharmacol Sci 20, 1993–2003.
57. Li L, Shen C, Nakamura E, Ando K, Signoretti S, Beroukhim R, Cowley GS, Lizotte P, Liberzon E, Bair S et al. (2013) SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. Cancer Cell 24, 738–750.
58. Denk H, Stumptner C, Fuchsbichler A, Müller T, Farr G, Müller W, Terracciano L and Zatloukal K (2006) Are the Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic hepatocytes related? J Pathol 208, 653–661.
59. Fukuo Y, Yamashina S, Sonoue H, Arakawa A, Nakadera E, Aoyama T, Uchiyama A, Kon K, Ikejima K and Watanabe S (2014) Abnormality of autophagic function and cathepsin expression in the liver from patients with non-alcoholic fatty liver disease. Hepatol Res 44, 1026–1036.
60. Gonzalez-Rodriguez A, Mayoral R, Agra N, Valdecantos MP, Pardo V, Miquilena-Colina ME, Vargas-Castrillón J, Lo Iacono O, Corazzari M, Fimia GM et al. (2014) Impaired autophagic flux is associated with increased endoplasmic reticulum stress during the development of NAFLD. Cell Death Dis 5, e1179.
61. Sabbieti MG, Agas D, Capitani M, Marchetti L, Concetti A, Vullo C, Catone G, Gabai V, Shifrin V, Sherman MY et al. (2015) Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent. Oncotarget 6, 3590–3599.
62. Gabai V, Venanzi FM, Bagashova E, Rud O, Mariotti F, Vullo C, Catone G, Sherman MY, Concetti A, Chursov A et al. (2014) Pilot study of p62 DNA vaccine in dogs with mammary tumors. Oncotarget 5, 12803–12810.
63. Gabai VL and Shifrin VI (2014) Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. Int Rev Immunol 33, 375–382.
64. Valencia T, Kim JY, Abu-Baker S, Moscat-Pardos J, Ahn CS, Reina-Campos M, Duran A, Castilla EA, Metallo CM, Diaz-Meco MT et al. (2014) Metabolic reprogramming of stromal fibroblasts through p62-mTORC1 signaling promotes inflammation and tumorigenesis. Cancer Cell 26, 121–135.
65. Moscat J and Diaz-Meco MT (2011) Feedback on fat: p62-mTORC1-autophagy connections. Cell 147, 724–727.
66. Ling J, Kang Y, Zhao R, Xia Q, Lee DF, Chang Z, Li J, Peng B, Fleming JB, Wang H et al. (2012) KrasG12D-induced IKK2/beta/NF-kappaB activation by IL-1alpha and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Cancer Cell 21, 105–120.
67. Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, He F, Boassa D, Perkins G, Ali SR et al. (2016) NF-kappaB restricts inflammasome activation via elimination of damaged mitochondria. Cell 164, 896–910.
68. Chen C, Deng M, Sun Q, Loughran P, Billiar TR and Scott MJ (2014) Lipopolysaccharide stimulates p62-dependent autophagy-like aggregate clearance in hepatocytes. Biomed Res Int 2014, 267350.
69. Duran A, Linares JF, Galvez AS, Wikenheiser K, Flores JM, Diaz-Meco MT and Moscat J (2008) The signaling adaptor p62 is an important NF-kappaB mediator in tumorigenesis. Cancer Cell 13, 343–354.
70. Puissant A, Robert G, Fenouille N, Luciano F, Cassuto JP, Raynaud S and Auberger P (2010) Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res 70, 1042–1052.
71. Puissant A, Fenouille N and Auberger P (2012) When autophagy meets cancer through p62/SQSTM1. Am J Cancer Res 2, 397–413.
72. Vegliante R, Desideri E, Di Leo L and Ciriolo MR (2016) Dehydroepiandrosterone triggers autophagic cell death in human hepatoma cell line HepG2 via JNK-mediated p62/SQSTM1 expression. Carcinogenesis 37, 233–244.
73. Yeh LY, Desideri E, Di Leo L and Ciriolo MR (2015) miR-372 inhibits p62 in head and neck squamous cell carcinoma in vitro and in vivo. Oncotarget 6, 6062–6075.
74. Williams JA, Thomas AM, Li G, Kong B, Zhan L, Inaba Y, Xie W, Ding WX and Guo GL (2012) Tissue specific induction of p62/Sqstm1 by farnesoid X receptor. PLoS One 7, e43961.
75. Liu XD, Ko S, Xu Y, Fattah EA, Xiang Q, Jagannath C, Ishii T, Komatsu M and Eissa NT (2012) Transient aggregation of ubiquitinated proteins is a cytosolic unfolded protein response to inflammation and endoplasmic reticulum stress. J Biol Chem 287, 19687–19698.
76. Bjorkoy G, Lamark T, Pankiv S, Øvervatn A, Brech A and Johansen T (2009) Monitoring autophagic degradation of p62/SQSTM1. Methods Enzymol 452, 181–197.
77. Morgan MJ and Thorburn A (2016) Measuring autophagy in the context of cancer. Adv Exp Med Biol 899, 121–143.
78. Jiang P and Mizushima N (2015) LC3- and p62-based biochemical methods for the analysis of autophagy progression in mammalian cells. Methods 75, 13–18.
79. Pursiheimo JP, Rantanen K, Heikkinen PT, Johansen T and Jaakkola PM (2009) Hypoxia-activated autophagy accelerates degradation of SQSTM1/p62. Oncogene 28, 334–344.
80. Thomes PG, Trambly CS, Fox HS, Tuma DJ and Donohue TM Jr (2015) Acute and chronic ethanol administration differentially modulate hepatic autophagy and transcription factor EB. Alcohol Clin Exp Res 39, 2354–2363.
81. Donohue Jr TM and Thomes PG (2014) Ethanol-induced oxidant stress modulates hepatic autophagy and proteasome activity. Redox Biol 3, 29–39.
82. Guo R, Xu X, Babcock SA, Zhang Y and Ren J (2015) Aldehyde dedydrogenase-2 plays a beneficial role in ameliorating chronic alcohol-induced hepatic steatosis and inflammation through regulation of autophagy. J Hepatol 62, 647–656.
83. Wu D, Wang X, Zhou R and Cederbaum A (2010) CYP2E1 enhances ethanol-induced lipid accumulation but impairs autophagy in HepG2 E47 cells. Biochem Biophys Res Commun 402, 116–122.
84. Manley S, Ni HM, Williams JA, Kong B, DiTacchio L, Guo G and Ding WX (2014) Farnesoid X receptor regulates forkhead Box O3a activation in ethanol-induced autophagy and hepatotoxicity. Redox Biol 2C, 991–1002.
85. Kansanen E, Kuosmanen SM, Leinonen H and Levonen AL (2013) The Keap1-Nrf2 pathway: mechanisms of activation and dysregulation in cancer. Redox Biol 1, 45–49.
86. Suzuki T and Yamamoto M (2015) Molecular basis of the Keap1-Nrf2 system. Free Radic Biol Med 88(Pt B), 93–100.
87. Jaramillo MC and Zhang DD (2013) The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 27, 2179–2191.
88. Kim HM, Han JW and Chan JY (2016) Nuclear Factor Erythroid-2 Like 1 (NFE2L1): structure, function and regulation. Gene 584, 17–25.
89. Mitsuishi Y, Motohashi H and Yamamoto M (2012) The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol 2, 200.
90. Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, Pronzato MA and Nitti M (2016) The Nrf2/HO-1 axis in cancer cell growth and chemoresistance. Oxid Med Cell Longev 2016, 1958174.
91. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD and Yamamoto M (1999) Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 13, 76–86.
92. Jiang T, Harder B, Rojo de la Vega M, Wong PK, Chapman E and Zhang DD (2015) p62 links autophagy and Nrf2 signaling. Free Radic Biol Med 88 (Pt B), 199–204.
93. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ and Calhoun ES (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475, 106–109.
94. Taguchi K, Fujikawa N, Komatsu M, Ishii T, Unno M, Akaike T, Motohashi H and Yamamoto M (2012) Keap1 degradation by autophagy for the maintenance of redox homeostasis. Proc Natl Acad Sci USA 109, 13561–13566.
95. Yang C, Tan YX, Yang GZ, Zhang J, Pan YF, Liu C, Fu J, Chen Y, Ding ZW, Dong LW et al. (2016) Gankyrin has an antioxidative role through the feedback regulation of Nrf2 in hepatocellular carcinoma. J Exp Med 213, 859–875.
96. Qin X, Wang X, Liu F, Morris LE, Wang X, Jiang B and Zhang Y (2016) Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancer. Cancer Lett 376, 83–94.
97. Chen W, Sun Z, Wang XJ, Jiang T, Huang Z, Fang D and Zhang DD (2009) Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell 34, 663–673.
98. Ma J, Cai H, Wu T, Sobhian B, Huo Y, Alcivar A, Mehta M, Cheung KL, Ganesan S, Kong AN et al. (2012) PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function. Mol Cell Biol 32, 1506–1517.
99. Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA, Tang X, Zheng N, Major MB and Moon RT (2012) Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein. J Biol Chem 287, 6539–6550.
100. O'Connell MA and Hayes JD (2015) The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic. Biochem Soc Trans 43, 687–689.
101. Shen H, Zhou S and Wang J (2013) The paradoxical role of Nrf2 in tumor biology. Crit Rev Eukaryot Gene Expr 23, 37–47.
102. Shelton P and Jaiswal AK (2013) The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene? FASEB J 27, 414–423.
103. Sporn MB and Liby KT (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12, 564–571.
104. Menegon S, Columbano A and Giordano S (2016) The dual roles of NRF2 in cancer. Trends Mol Med 22, 578–593.
105. Suzuki T, Motohashi H and Yamamoto M (2013) Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci 34, 340–346.
106. Hayes JD and McMahon M (2009) NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34, 176–188.
107. Bishayee A, Barnes KF, Bhatia D, Darvesh AS and Carroll RT (2010) Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev Res (Phila) 3, 753–763.
108. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H and Yamamoto M (2004) Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 64, 6424–6431.
109. Kitamura Y, Umemura T, Kanki K, Kodama Y, Kitamoto S, Saito K, Itoh K, Yamamoto M, Masegi T, Nishikawa A et al. (2007) Increased susceptibility to hepatocarcinogenicity of Nrf2-deficient mice exposed to 2-amino-3-methylimidazo[4,5-f]quinoline. Cancer Sci 98, 19–24.
110. Osburn WO, Karim B, Dolan PM, Liu G, Yamamoto M, Huso DL and Kensler TW (2007) Increased colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon dextran sulfate treatment. Int J Cancer 121, 1883–1891.
111. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, Talalay P and Kensler TW (2001) Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci USA 98, 3410–3415.
112. Xu C, Huang MT, Shen G, Yuan X, Lin W, Khor TO, Conney AH and Kong AN (2006) Inhibition of 7,12-dimethylbenz(a)anthracene-induced skin tumorigenesis in C57BL/6 mice by sulforaphane is mediated by nuclear factor E2-related factor 2. Cancer Res 66, 8293–8296.
113. Khor TO, Huang MT, Prawan A, Liu Y, Hao X, Yu S, Cheung WK, Chan JY, Reddy BS, Yang CS et al. (2008) Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila) 1, 187–191.
114. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, Asamura H, Yamamoto M and Hirohashi S (2008) Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci USA 105, 13568–13573.
115. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M and Hirohashi S (2008) Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 135, 1358–1368, 1368 e1–4.
116. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S and Yamamoto M (2006) Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol Cell 21, 689–700.
117. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T et al. (2008) Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 68, 1303–1309.
118. Schulze K, Imbeaud S, Letouzé E, Alexandrov LB, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F et al. (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47, 505–511.
119. Totoki Y, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura H et al. (2014) Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46, 1267–1273.
120. Nioi P and Nguyen T (2007) A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem Biophys Res Commun 362, 816–821.
121. Konstantinopoulos PA, Spentzos D, Fountzilas E, Francoeur N, Sanisetty S, Grammatikos AP, Hecht JL and Cannistra SA (2011) Keap1 mutations and Nrf2 pathway activation in epithelial ovarian cancer. Cancer Res 71, 5081–5089.
122. Cancer Genome Atlas Research N (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519–525.
123. Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, Lawrence MS et al. (2013) Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology 58, 1693–1702.
124. Guichard C, Amaddeo G, Imbeaud S, Ladeiro Y, Pelletier L, Maad IB, Calderaro J, Bioulac-Sage P, Letexier M, Degos F et al. (2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet 44, 694–698.
125. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, Han JY, Eom HS, Yoo NJ and Lee SH (2010) Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220, 446–451.
126. Satoh H, Moriguchi T, Takai J, Ebina M and Yamamoto M (2013) Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 73, 4158–4168.
127. Satoh H, Moriguchi T, Saigusa D, Baird L, Yu L, Rokutan H, Igarashi K, Ebina M, Shibata T and Yamamoto M (2016) NRF2 intensifies host defense systems to prevent lung carcinogenesis, but after tumor initiation accelerates malignant cell growth. Cancer Res 76, 3088–3096.
128. Hayes JD and McMahon M (2006) The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol Cell 21, 732–734.
129. Mitsuishi Y, Taguchi K, Kawatani Y, Shibata T, Nukiwa T, Aburatani H, Yamamoto M and Motohashi H (2012) Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell 22, 66–79.
130. DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE et al. (2015) NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet 47, 1475–1481.
131. Peiris-Pages M, Martinez-Outschoorn UE, Sotgia F and Lisanti MP (2015) Metastasis and oxidative stress: are antioxidants a metabolic driver of progression? Cell Metab 22, 956–958.
132. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, Leitch AM, Johnson TM, DeBerardinis RJ and Morrison SJ (2015) Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527, 186–191.
133. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyürek LM, Lindahl P, Nilsson J et al. (2015) Antioxidants can increase melanoma metastasis in mice. Sci Transl Med, 7, 308re8.
134. Harris IS and Brugge JS (2015) Cancer: the enemy of my enemy is my friend. Nature 527, 170–171.
135. Wang H, Liu X, Long M, Huang Y, Zhang L, Zhang R, Zheng Y, Liao X, Wang Y, Liao Q et al. (2016) NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Sci Transl Med 8, 334ra51.
136. Liu B, Fang M, He Z, Cui D, Jia S, Lin X, Xu X, Zhou T and Liu W (2015) Hepatitis B virus stimulates G6PD expression through HBx-mediated Nrf2 activation. Cell Death Dis 6, e1980.
137. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A and Naccarato R (1995) Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 22, 449–456.
138. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K and Nakamura H (2000) Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 95, 1041–1050.
139. Furutani T, Hino K, Okuda M, Gondo T, Nishina S, Kitase A, Korenaga M, Xiao SY, Weinman SA, Lemon SM et al. (2006) Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130, 2087–2098.
140. Silva-Gomes S, Santos AG, Caldas C, Silva CM, Neves JV, Lopes J, Carneiro F, Rodrigues PN and Duarte TL (2014) Transcription factor NRF2 protects mice against dietary iron-induced liver injury by preventing hepatocytic cell death. J Hepatol 60, 354–361.
141. Cao JY and Dixon SJ (2016) Mechanisms of ferroptosis. Cell Mol Life Sci 73, 2195–2209.
142. Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R and Tang D (2016) Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology 63, 173–184.
143. Zhou S, Ye W, Shao Q, Zhang M and Liang J (2013) Nrf2 is a potential therapeutic target in radioresistance in human cancer. Crit Rev Oncol Hematol 88, 706–715.
144. Xia M, Yu H, Gu S, Xu Y, Su J, Li H, Kang J and Cui M (2014) p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system. Int J Oncol 45, 2341–2348.
145. Ryoo IG, Choi BH and Kwak MK (2015) Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget 6, 8167–8184.
146. Yard BD, Adams DJ, Chie EK, Tamayo P, Battaglia JS, Gopal P, Rogacki K, Pearson BE, Phillips J, Raymond DP et al. (2016) A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun 7, 11428.
147. Wakabayashi N, Shin S, Slocum SL, Agoston ES, Wakabayashi J, Kwak MK, Misra V, Biswal S, Yamamoto M and Kensler TW (2010) Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Sci Signal 3, ra52.
148. Wakabayashi N, Skoko JJ, Chartoumpekis DV, Kimura S, Slocum SL, Noda K, Palliyaguru DL, Fujimuro M, Boley PA, Tanaka Y et al. (2014) Notch-Nrf2 axis: regulation of Nrf2 gene expression and cytoprotection by notch signaling. Mol Cell Biol 34, 653–663.
149. Wei Y, Gong J, Thimmulappa RK, Kosmider B, Biswal S and Duh EJ (2013) Nrf2 acts cell-autonomously in endothelium to regulate tip cell formation and vascular branching. Proc Natl Acad Sci USA 110, E3910–E3918.
150. Wakabayashi N, Chartoumpekis DV and Kensler TW (2015) Crosstalk between Nrf2 and Notch signaling. Free Radic Biol Med 88 (Pt B), 158–167.
151. Zhao Q, Mao A, Yan J, Sun C, Di C, Zhou X, Li H, Guo R and Zhang H (2016) Downregulation of Nrf2 promotes radiation-induced apoptosis through Nrf2 mediated Notch signaling in non-small cell lung cancer cells. Int J Oncol 48, 765–773.
152. Yamaguchi M, Murakami S, Yoneda T, Nakamura M, Zhang L, Uezumi A, Fukuda S, Kokubo H, Tsujikawa K and Fukada S (2015) Evidence of Notch-Hesr-Nrf2 axis in muscle stem cells, but absence of Nrf2 has no effect on their quiescent and undifferentiated state. PLoS One 10, e0138517.
153. Paul MK, Bisht B, Darmawan DO, Chiou R, Ha VL, Wallace WD, Chon AT, Hegab AE, Grogan T, Elashoff DA et al. (2014) Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent Notch signaling. Cell Stem Cell 15, 199–214.
154. Kim JH, Thimmulappa RK, Kumar V, Cui W, Kumar S, Kombairaju P, Zhang H, Margolick J, Matsui W, Macvittie T et al. (2014) NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest 124, 730–741.
155. DiDonato JA, Mercurio F and Karin M (2012) NF-kappaB and the link between inflammation and cancer. Immunol Rev 246, 379–400.
156. Grivennikov SI, Greten FR and Karin M (2010) Immunity, inflammation, and cancer. Cell 140, 883–899.
157. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441, 431–436.
158. Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H and Maluccio MA (2009) NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Lett 278, 145–155.
159. Luedde T, Beraza N, Kotsikoris V, vanLoo G, Nenci A, De Vos R, Roskams T, Trautwein C and Pasparakis M (2007) Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11, 119–132.
160. Seki E and Brenner DA (2007) The role of NF-kappaB in hepatocarcinogenesis: promoter or suppressor? J Hepatol 47, 307–309.
161. Maeda S, Kamata H, Luo JL, Leffert H and Karin M (2005) IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 121, 977–990.
162. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K, Browning JL, Goossens N, Nakagawa S, Gunasekaran G et al. (2015) Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol 16, 1235–1244.
163. Zotti T, Scudiero I, Settembre P, Ferravante A, Mazzone P, D'Andrea L, Reale C, Vito P and Stilo R (2014) TRAF6-mediated ubiquitination of NEMO requires p62/sequestosome-1. Mol Immunol 58, 27–31.
164. Starczynowski DT, Lockwood WW, Deléhouzée S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL et al. (2011) TRAF6 is an amplified oncogene bridging the RAS and NF-kappaB pathways in human lung cancer. J Clin Invest 121, 4095–4105.
165. Wei H, Wang C, Croce CM and Guan JL (2014) p62/SQSTM1 synergizes with autophagy for tumor growth in vivo. Genes Dev 28, 1204–1216.
166. Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL et al. (2014) Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-kappaB gene network. Cell Rep 8, 1328–1338.
167. Seibold K and Ehrenschwender M (2015) p62 regulates CD40-mediated NFkappaB activation in macrophages through interaction with TRAF6. Biochem Biophys Res Commun 464, 330–335.
168. Wooten MW, Geetha T, Seibenhener ML, Babu JR, Diaz-Meco MT and Moscat J (2005) The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination. J Biol Chem 280, 35625–35629.
169. Duran A, Serrano M, Leitges M, Flores JM, Picard S, Brown JP, Moscat J and Diaz-Meco MT (2004) The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 6, 303–309.
170. McManus S and Roux S (2012) The adaptor protein p62/SQSTM1 in osteoclast signaling pathways. J Mol Signal 7, 1.
171. Yip KH, Feng H, Pavlos NJ, Zheng MH and Xu J (2006) p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone. Am J Pathol 169, 503–514.
172. Chamoux E, McManus S, Laberge G, Bisson M and Roux S (2013) Involvement of kinase PKC-zeta in the p62/p62(P392L)-driven activation of NF-kappaB in human osteoclasts. Biochim Biophys Acta 1832, 475–484.
173. Chang KH, Sengupta A, Nayak RC, Duran A, Lee SJ, Pratt RG, Wellendorf AM, Hill SE, Watkins M, Gonzalez-Nieto D et al. (2014) p62 is required for stem cell/progenitor retention through inhibition of IKK/NF-kappaB/Ccl4 signaling at the bone marrow macrophage-osteoblast niche. Cell Rep 9, 2084–2097.
174. Martin P, Diaz-Meco MT and Moscat J (2006) The signaling adapter p62 is an important mediator of T helper 2 cell function and allergic airway inflammation. EMBO J 25, 3524–3533.
175. Diaz-Meco MT and Moscat J (2012) The atypical PKCs in inflammation: NF-kappaB and beyond. Immunol Rev 246, 154–167.
176. Paul S, Traver MK, Kashyap AK, Washington MA, Latoche JR and Schaefer BC (2014) T cell receptor signals to NF-kappaB are transmitted by a cytosolic p62-Bcl10-Malt1-IKK signalosome. Sci Signal 7, ra45.
177. Lee HM, Shin DM, Yuk JM, Shi G, Choi DK, Lee SH, Huang SM, Kim JM, Kim CD, Lee JH et al. (2011) Autophagy negatively regulates keratinocyte inflammatory responses via scaffolding protein p62/SQSTM1. J Immunol 186, 1248–1258.
178. Kanayama M, Inoue M, Danzaki K, Hammer G, He YW and Shinohara ML (2015) Autophagy enhances NFkappaB activity in specific tissue macrophages by sequestering A20 to boost antifungal immunity. Nat Commun 6, 5779.
179. Kim JY and Ozato K (2009) The sequestosome 1/p62 attenuates cytokine gene expression in activated macrophages by inhibiting IFN regulatory factor 8 and TNF receptor-associated factor 6/NF-kappaB activity. J Immunol 182, 2131–2140.
180. Laplante M and Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149, 274–293.
181. Ashworth RE and Wu J (2014) Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol 6, 776–782.
182. Zhou L, Huang Y, Li J and Wang Z (2010) The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol 27, 255–261.
183. Zhu AX, Kudo M, Assenat E, Cattan S, Kang YK, Lim HY, Poon RT, Blanc JF, Vogel A, Chen CL et al. (2014) Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312, 57–67.
184. Umemura A, Park EJ, Taniguchi K, Lee JH, Shalapour S, Valasek MA, Aghajan M, Nakagawa H, Seki E, Hall MN et al. (2014) Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab 20, 133–144.
185. Linares JF, Duran A, Reina-Campos M, Aza-Blanc P, Campos A, Moscat J and Diaz-Meco MT (2015) Amino acid activation of mTORC1 by a PB1-domain-driven kinase complex cascade. Cell Rep 12, 1339–1352.
186. Linares JF, Duran A, Reina-Campos M, Aza-Blanc P, Campos A, Moscat J and Diaz-Meco MT (2013) K63 polyubiquitination and activation of mTOR by the p62-TRAF6 complex in nutrient-activated cells. Mol Cell 51, 283–296.
187. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, Ishimura R, Saito T, Yang Y, Kouno T, Fukutomi T et al. (2013) Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell 51, 618–631.
188. Hashimoto K, Simmons AN, Kajino-Sakamoto R, Tsuji Y and Ninomiya-Tsuji J (2016) TAK1 regulates the Nrf2 antioxidant system through modulating p62/SQSTM1. Antioxid Redox Signal [Epub ahead of print].
189. Mizui T, Yamashina S, Tanida I, Takei Y, Ueno T, Sakamoto N, Ikejima K, Kitamura T, Enomoto N, Sakai T et al. (2010) Inhibition of hepatitis C virus replication by chloroquine targeting virus-associated autophagy. J Gastroenterol 45, 195–203.
190. Sir D, Chen WL, Choi J, Wakita T, Yen TS and Ou JH (2008) Induction of incomplete autophagic response by hepatitis C virus via the unfolded protein response. Hepatology 48, 1054–1061.
191. Sir D, Kuo CF, Tian Y, Liu HM, Huang EJ, Jung JU, Machida K and Ou JH (2012) Replication of hepatitis C virus RNA on autophagosomal membranes. J Biol Chem 287, 18036–18043.
192. Vescovo T, Refolo G, Romagnoli A, Ciccosanti F, Corazzari M, Alonzi T and Fimia GM (2014) Autophagy in HCV infection: keeping fat and inflammation at bay. Biomed Res Int 2014, 265353.
193. Ploen D and Hildt E (2015) Hepatitis C virus comes for dinner: how the hepatitis C virus interferes with autophagy. World J Gastroenterol 21, 8492–8507.
194. Ke PY and Chen SS (2014) Autophagy in hepatitis C virus-host interactions: potential roles and therapeutic targets for liver-associated diseases. World J Gastroenterol 20, 5773–5793.
195. Dash S, Chava S, Aydin Y, Chandra PK, Ferraris P, Chen W, Balart LA, Wu T and Garry RF (2016) Hepatitis C virus infection induces autophagy as a prosurvival mechanism to alleviate hepatic ER-stress response. Viruses 8. pii: E150.
196. Kim J, Kundu M, Viollet B and Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13, 132–141.
197. Schneider JL and Cuervo AM (2014) Liver autophagy: much more than just taking out the trash. Nat Rev Gastroenterol Hepatol 11, 187–200.
198. Egan DF, Shackelford DB, Mihaylova MM, Gelino S, Kohnz RA, Mair W, Vasquez DS, Joshi A, Gwinn DM, Taylor R et al. (2011) Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 331, 456–461.
199. Menon S, Yecies JL, Zhang HH, Howell JJ, Nicholatos J, Harputlugil E, Bronson RT, Kwiatkowski DJ and Manning BD (2012) Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci Signal 5, ra24.
200. Xu LZ, Li SS, Zhou W, Kang ZJ, Zhang QX, Kamran M, Xu J, Liang DP, Wang CL, Hou ZJ et al. (2016) p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA. Oncogene, doi: 10.1038/onc.2016.202.
201. Ding WX (2010) Role of autophagy in liver physiology and pathophysiology. World J Biol Chem 1, 3–12.
202. Czaja MJ, Ding WX, Donohue TM Jr, Friedman SL, Kim JS, Komatsu M, Lemasters JJ, Lemoine A, Lin JD et al. (2013) Functions of autophagy in normal and diseased liver. Autophagy 9, 1131–1158.
203. Lee YJ and Jang BK (2015) The role of autophagy in hepatocellular carcinoma. Int J Mol Sci 16, 26629–26643.
204. Singh R, Kaushik S, Wang Y, Xiang Y, Novak I, Komatsu M, Tanaka K, Cuervo AM and Czaja MJ (2009) Autophagy regulates lipid metabolism. Nature 458, 1131–1135.
205. Takamura A, Komatsu M, Hara T, Sakamoto A, Kishi C, Waguri S, Eishi Y, Hino O, Tanaka K and Mizushima N (2011) Autophagy-deficient mice develop multiple liver tumors. Genes Dev 25, 795–800.
206. Rosenfeldt MT, O'Prey J, Morton JP, Nixon C, MacKay G, Mrowinska A, Au A, Rai TS, Zheng L, Ridgway R et al. (2013) p53 status determines the role of autophagy in pancreatic tumour development. Nature 504, 296–300.
207. Ni HM, Woolbright BL, Williams J, Copple B, Cui W, Luyendyk JP, Jaeschke H and Ding WX (2014) Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy. J Hepatol 61, 617–625.
208. Johansen T and Lamark T (2011) Selective autophagy mediated by autophagic adapter proteins. Autophagy 7, 279–296.
209. Kraft C, Peter M and Hofmann K (2010) Selective autophagy: ubiquitin-mediated recognition and beyond. Nat Cell Biol 12, 836–841.
210. Birgisdottir AB, Lamark T and Johansen T (2013) The LIR motif - crucial for selective autophagy. J Cell Sci 126 (Pt 15), 3237–3247.
211. Antonucci L, Fagman JB, Kim JY, Todoric J, Gukovsky I, Mackey M, Ellisman MH and Karin M (2015) Basal autophagy maintains pancreatic acinar cell homeostasis and protein synthesis and prevents ER stress. Proc Natl Acad Sci USA 112, E6166–E6174.
212. Yang H, Ni HM, Guo F, Ding Y, Shi YH, Lahiri P, Fröhlich LF, Rülicke T, Smole C, Schmidt VC et al. (2016) Sequestosome-1/p62 is associated with autophagic removal of excess hepatic endoplasmic reticulum in mice. J Biol Chem pii: jbc.M116.739821. [Epub ahead of print].
213. Tsuchiya M, Ogawa H, Koujin T, Kobayashi S, Mori C, Hiraoka Y and Haraguchi T (2016) Depletion of autophagy receptor p62/SQSTM1 enhances the efficiency of gene delivery in mammalian cells. FEBS Lett, doi: 10.1002/1873-3468.12262.
214. White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12, 401–410.
215. White E (2015) The role for autophagy in cancer. J Clin Invest 125, 42–46.
216. Ziparo E, Petrungaro S, Marini ES, Starace D, Conti S, Facchiano A, Filippini A and Giampietri C (2013) Autophagy in prostate cancer and androgen suppression therapy. Int J Mol Sci 14, 12090–12106.
217. Edinger AL and Thompson CB (2003) Defective autophagy leads to cancer. Cancer Cell 4, 422–424.
218. Kondo Y, Kanzawa T, Sawaya R and Kondo S (2005) The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 5, 726–734.
219. Qiang L, Zhao B, Ming M, Wang N, He TC, Hwang S, Thorburn A and He YY (2014) Regulation of cell proliferation and migration by p62 through stabilization of Twist1. Proc Natl Acad Sci USA 111, 9241–9246.
220. Goodall ML, Fitzwalter BE, Zahedi S, Wu M, Rodriguez D, Mulcahy-Levy JM, Green DR, Morgan M, Cramer SD and Thorburn A (2016) The autophagy machinery controls cell death switching between apoptosis and necroptosis. Dev Cell 37, 337–349.
221. Matsumoto G, Wada K, Okuno M, Kurosawa M and Nukina N (2011) Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins. Mol Cell 44, 279–289.
222. Ro SH, Semple IA, Park H, Park H, Park HW, Kim M, Kim JS and Lee JH (2014) Sestrin2 promotes Unc-51-like kinase 1 mediated phosphorylation of p62/sequestosome-1. FEBS J 281, 3816–3827.
223. Pilli M, Arko-Mensah J, Ponpuak M, Roberts E, Master S, Mandell MA, Dupont N, Ornatowski W, Jiang S, Bradfute SB et al. (2012) TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity 37, 223–234.
224. Lim J, Lachenmayer ML, Wu S, Liu W, Kundu M, Wang R, Komatsu M, Oh YJ, Zhao Y and Yue Z (2015) Proteotoxic stress induces phosphorylation of p62/SQSTM1 by ULK1 to regulate selective autophagic clearance of protein aggregates. PLoS Genet 11, e1004987.
225. Xu H, Yu H, Zhang X, Shen X, Zhang K, Sheng H, Dai S and Gao H (2013) UNC51-like kinase 1 as a potential prognostic biomarker for hepatocellular carcinoma. Int J Clin Exp Pathol 6, 711–717.
226. Wang M and Kaufman RJ (2014) The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 14, 581–597.
227. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ and Diehl JA (2003) Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23, 7198–7209.
228. He CH, Gong P, Hu B, Stewart D, Choi ME, Choi AM and Alam J (2001) Identification of activating transcription factor 4 (ATF4) as an Nrf2-interacting protein. Implication for heme oxygenase-1 gene regulation. J Biol Chem 276, 20858–20865.
229. B'Chir W, Maurin AC, Carraro V, Averous J, Jousse C, Muranishi Y, Parry L, Stepien G, Fafournoux P and Bruhat A (2013) The eIF2alpha/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res 41, 7683–7699.
230. Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J, Yuan CL, Krokowski D, Wang S, Hatzoglou M et al. (2013) ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol 15, 481–490.
231. Shen Y, Yang J, Zhao J, Xiao C, Xu C and Xiang Y (2015) The switch from ER stress-induced apoptosis to autophagy via ROS-mediated JNK/p62 signals: a survival mechanism in methotrexate-resistant choriocarcinoma cells. Exp Cell Res 334, 207–218.
232. Park HW, Park H, Ro SH, Jang I, Semple IA, Kim DN, Kim M, Nam M, Zhang D, Yin L et al. (2014) Hepatoprotective role of Sestrin2 against chronic ER stress. Nat Commun 5, 4233.
233. Saveljeva S, Cleary P, Mnich K, Ayo A, Pakos-Zebrucka K, Patterson JB, Logue SE and Samali A (2016) Endoplasmic reticulum stress-mediated induction of SESTRIN 2 potentiates cell survival. Oncotarget 7, 12254–12266.
234. Cha-Molstad H, Sung KS, Hwang J, Kim KA, Yu JE, Yoo YD, Jang JM, Han DH, Molstad M, Kim JG et al. (2015) Amino-terminal arginylation targets endoplasmic reticulum chaperone BiP for autophagy through p62 binding. Nat Cell Biol 17, 917–929.
235. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, Kleinert R, Prinz M, Aguzzi A and Denk H (2002) p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 160, 255–263.
236. Yoshida H (2007) ER stress and diseases. FEBS J 274, 630–658.
237. Lindholm D, Wootz H and Korhonen L (2006) ER stress and neurodegenerative diseases. Cell Death Differ 13, 385–392.
238. DeJesus R, Moretti F, McAllister G, Wang Z, Bergman P, Liu S, Frias E, Alford J, Reece-Hoyes JS, Lindeman A et al. (2016) Functional CRISPR screening identifies the ufmylation pathway as a regulator of SQSTM1/p62. Elife 5, e17290.
239. Miyagawa K, Oe S, Honma Y, Izumi H, Baba R and Harada M (2016) Lipid-induced endoplasmic reticulum stress impairs selective autophagy at the step of autophagosome-lysosome fusion in hepatocytes. Am J Pathol 186, 1861–1873.
240. Fu S, Yang L, Li P, Hofmann O, Dicker L, Hide W, Lin X, Watkins SM, Ivanov AR and Hotamisligil GS (2011) Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity. Nature 473, 528–531.
241. Ogata M, Hino S, Saito A, Morikawa K, Kondo S, Kanemoto S, Murakami T, Taniguchi M, Tanii I, Yoshinaga K et al. (2006) Autophagy is activated for cell survival after endoplasmic reticulum stress. Mol Cell Biol 26, 9220–9231.
242. Rashid HO, Yadav RK, Kim HR and Chae HJ (2015) ER stress: autophagy induction, inhibition and selection. Autophagy 11, 1956–1977.
243. Asselah T, Bièche I, Mansouri A, Laurendeau I, Cazals-Hatem D, Feldmann G, Bedossa P, Paradis V, Martinot-Peignoux M, Lebrec D et al. (2010) In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol 221, 264–274.
244. Ke PY and Chen SS (2011) Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. J Clin Invest 121, 37–56.
245. Ke PY and Chen SS (2012) Hepatitis C virus and cellular stress response: implications to molecular pathogenesis of liver diseases. Viruses 4, 2251–2290.
246. Chan SW (2014) Unfolded protein response in hepatitis C virus infection. Front Microbiol 5, 233.
247. Tardif KD, Mori K and Siddiqui A (2002) Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol 76, 7453–7459.
248. Ke PY and Chen SS (2011) Autophagy: a novel guardian of HCV against innate immune response. Autophagy 7, 533–535.
249. Medvedev R, Ploen D and Hildt E (2016) HCV and oxidative stress: implications for HCV life cycle and HCV-associated pathogenesis. Oxid Med Cell Longev 2016, 9012580.
250. Yadav RK, Chae SW, Kim HR and Chae HJ (2014) Endoplasmic reticulum stress and cancer. J Cancer Prev 19, 75–88.
251. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, Hada A, Arai M, Wakatsuki T, Matsubara O et al. (2003) Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 38, 605–614.
252. Nakagawa H, Umemura A, Taniguchi K, Font-Burgada J, Dhar D, Ogata H, Zhong Z, Valasek MA, Seki E, Hidalgo J et al. (2014) ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 26, 331–343.
253. Oakes SA and Papa FR (2015) The role of endoplasmic reticulum stress in human pathology. Annu Rev Pathol 10, 173–194.
254. Toshima T, Shirabe K, Fukuhara T, Ikegami T, Yoshizumi T, Soejima Y, Ikeda T, Okano S and Maehara Y (2014) Suppression of autophagy during liver regeneration impairs energy charge and hepatocyte senescence in mice. Hepatology 60, 290–300.
255. Ni HM, Boggess N, McGill MR, Lebofsky M, Borude P, Apte U, Jaeschke H and Ding WX (2012) Liver-specific loss of Atg5 causes persistent activation of Nrf2 and protects against acetaminophen-induced liver injury. Toxicol Sci 127, 438–450.
256. Kohler UA, Kurinna S, Schwitter D, Marti A, Schäfer M, Hellerbrand C, Speicher T and Werner S (2014) Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. Hepatology 60, 670–678.
257. Haga S, Ozawa T, Yamada Y, Morita N, Nagashima I, Inoue H, Inaba Y, Noda N, Abe R, Umezawa K et al. (2014) p62/SQSTM1 plays a protective role in oxidative injury of steatotic liver in a mouse hepatectomy model. Antioxid Redox Signal 21, 2515–2530.
258. Beyer TA, Xu W, Teupser D, auf dem Keller U, Bugnon P, Hildt E, Thiery J, Kan YW and Werner S (2008) Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance. EMBO J 27, 212–223.
259. Enomoto A, Itoh K, Nagayoshi E, Haruta J, Kimura T, O'Connor T, Harada T and Yamamoto M (2001) High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol Sci 59, 169–177.
260. Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler TW and Yamamoto M (2006) Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun 339, 79–88.
261. Lee LY, Harberg C, Matkowskyj KA, Cook S, Roenneburg D, Werner S, Johnson DA, Johnson JA and Foley DP (2016) Cell-specific over-activation of Nrf2-mediated gene expression in myeloid cells decreases hepatic ischemia reperfusion injury. Liver Transpl, doi: 10.1002/lt.24473.
262. Ni HM, McGill MR, Chao X, Du K, Williams JA, Xie Y, Jaeschke H and Ding WX (2016) Removal of acetaminophen-protein adducts by autophagy protects against acetaminophen-induced liver injury in mice. J Hepatol 65, 354–362.
263. Pan JA, Sun Y, Jiang YP, Bott AJ, Jaber N, Dou Z, Yang B, Chen JS, Catanzaro JM, Du C et al. (2016) TRIM21 ubiquitylates SQSTM1/p62 and suppresses protein sequestration to regulate redox homeostasis. Mol Cell 61, 720–733.
264. Bae SH, Sung SH, Oh SY, Lim JM, Lee SK, Park YN, Lee HE, Kang D and Rhee SG (2013) Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage. Cell Metab 17, 73–84.
265. Bettermann K, Hohensee T and Haybaeck J (2014) Steatosis and steatohepatitis: complex disorders. Int J Mol Sci 15, 9924–9944.
266. Wong RJ, Cheung R and Ahmed A (2014) Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 59, 2188–2195.
267. Buzzetti E, Pinzani M and Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65, 1038–1048.
268. Day CP and James OF (1998) Steatohepatitis: a tale of two “hits”? Gastroenterology 114, 842–845.
269. Ashraf NU and Sheikh TA (2015) Endoplasmic reticulum stress and Oxidative stress in the pathogenesis of Non-alcoholic fatty liver disease. Free Radic Res 49, 1405–1418.
270. Sumida Y, Niki E, Naito Y and Yoshikawa T (2013) Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic Res 47, 869–880.
271. Tariq Z, Green CJ and Hodson L (2014) Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)? Liver Int 34, e180–e190.
272. Rolo AP, Teodoro JS and Palmeira CM (2012) Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 52, 59–69.
273. Koek GH, Liedorp PR and Bast A (2011) The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta 412, 1297–1305.
274. Albano E, Mottaran E, Occhino G, Reale E and Vidali M (2005) Review article: role of oxidative stress in the progression of non-alcoholic steatosis. Aliment Pharmacol Ther 22 (Suppl 2), 71–73.
275. Del Ben M, Polimeni L, Carnevale R, Bartimoccia S, Nocella C, Baratta F, Loffredo L, Pignatelli P, Violi F and Angelico F (2014) NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 14, 81.
276. Wang M and Kaufman RJ (2016) Protein misfolding in the endoplasmic reticulum as a conduit to human disease. Nature 529, 326–335.
277. Pagliassotti MJ (2012) Endoplasmic reticulum stress in nonalcoholic fatty liver disease. Annu Rev Nutr 32, 17–33.
278. Zhou H and Liu R (2014) ER stress and hepatic lipid metabolism. Front Genet 5, 112.
279. Li J, Huang J, Li JS, Chen H, Huang K and Zheng L (2012) Accumulation of endoplasmic reticulum stress and lipogenesis in the liver through generational effects of high fat diets. J Hepatol 56, 900–907.
280. Peverill W, Powell LW and Skoien R (2014) Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 15, 8591–8638.
281. Anderson N and Borlak J (2008) Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol Rev 60, 311–357.
282. Brunt EM (2009) Histopathology of non-alcoholic fatty liver disease. Clin Liver Dis 13, 533–544.
283. Czaja MJ (2016) Function of autophagy in nonalcoholic fatty liver disease. Dig Dis Sci 61, 1304–1313.
284. Lavallard VJ and Gual P (2014) Autophagy and non-alcoholic fatty liver disease. Biomed Res Int 2014, 120179.
285. Liu W, Baker RD, Bhatia T, Zhu L and Baker SS (2016) Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci 73, 1969–1987.
286. Kwanten WJ, Martinet W, Michielsen PP and Francque SM (2014) Role of autophagy in the pathophysiology of nonalcoholic fatty liver disease: a controversial issue. World J Gastroenterol 20, 7325–7338.
287. Dong H and Czaja MJ (2011) Regulation of lipid droplets by autophagy. Trends Endocrinol Metab 22, 234–240.
288. Ward C, Martinez-Lopez N, Otten EG, Carroll B, Maetzel D, Singh R, Sarkar S and Korolchuk VI (2016) Autophagy, lipophagy and lysosomal lipid storage disorders. Biochim Biophys Acta 1861, 269–284.
289. Lee SJ, Pfluger PT, Kim JY, Nogueiras R, Duran A, Pagès G, Pouysségur J, Tschöp MH, Diaz-Meco MT and Moscat J (2010) A functional role for the p62-ERK1 axis in the control of energy homeostasis and adipogenesis. EMBO Rep 11, 226–232.
290. Harada H, Warabi E, Matsuki T, Yanagawa T, Okada K, Uwayama J, Ikeda A, Nakaso K, Kirii K, Noguchi N et al. (2013) Deficiency of p62/Sequestosome 1 causes hyperphagia due to leptin resistance in the brain. J Neurosci 33, 14767–14777.
291. Muller TD, Lee SJ, Jastroch M, Kabra D, Stemmer K, Aichler M, Abplanalp B, Ananthakrishnan G, Bhardwaj N, Collins S et al. (2013) p62 links beta-adrenergic input to mitochondrial function and thermogenesis. J Clin Invest 123, 469–478.
292. Chambel SS, Santos-Goncalves A and Duarte TL (2015) The dual role of Nrf2 in nonalcoholic fatty liver disease: regulation of antioxidant defenses and hepatic lipid metabolism. Biomed Res Int 2015, 597134.
293. Zhang YK, Yeager RL, Tanaka Y and Klaassen CD (2010) Enhanced expression of Nrf2 in mice attenuates the fatty liver produced by a methionine- and choline-deficient diet. Toxicol Appl Pharmacol 245, 326–334.
294. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR et al. (2009) Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 30, 1024–1031.
295. Kitteringham NR, Abdullah A, Walsh J, Randle L, Jenkins RE, Sison R, Goldring CE, Powell H, Sanderson C, Williams S et al. (2010) Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver. J Proteomics 73, 1612–1631.
296. Tanaka Y, Aleksunes LM, Yeager RL, Gyamfi MA, Esterly N, Guo GL and Klaassen CD (2008) NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet. J Pharmacol Exp Ther 325, 655–664.
297. Tanaka Y, Ikeda T, Yamamoto K, Ogawa H and Kamisako T (2012) Dysregulated expression of fatty acid oxidation enzymes and iron-regulatory genes in livers of Nrf2-null mice. J Gastroenterol Hepatol 27, 1711–1717.
298. Okada K, Warabi E, Sugimoto H, Horie M, Gotoh N, Tokushige K, Hashimoto E, Utsunomiya H, Takahashi H, Ishii T et al. (2013) Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. J Gastroenterol 48, 620–632.
299. Shin S, Wakabayashi J, Yates MS, Wakabayashi N, Dolan PM, Aja S, Liby KT, Sporn MB, Yamamoto M and Kensler TW (2009) Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur J Pharmacol 620, 138–144.
300. Slocum SL, Skoko JJ, Wakabayashi N, Aja S, Yamamoto M, Kensler TW and Chartoumpekis DV (2016) Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet. Arch Biochem Biophys 591, 57–65.
301. Park JS, Kang DH, Lee da H and Bae SH (2015) Concerted action of p62 and Nrf2 protects cells from palmitic acid-induced lipotoxicity. Biochem Biophys Res Commun 466, 131–137.
302. Richieri GV and Kleinfeld AM (1995) Unbound free fatty acid levels in human serum. J Lipid Res 36, 229–240.
303. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P and McClain CJ (2007) Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 46, 823–830.
304. Moravcova A, Červinková Z, Kučera O, Mezera V, Rychtrmoc D and Lotková H (2016) The effect of oleic and palmitic acid on induction of steatosis and cytotoxicity on rat hepatocytes in primary culture. Physiol Res 64 (Suppl 5), S627–S636.
305. Chavez-Tapia NC, Rosso N, Uribe M, Bojalil R and Tiribelli C (2013) Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Ann Hepatol 13, 113–120.
306. Xu W, Shao L, Zhou C, Wang H and Guo J (2011) Upregulation of Nrf2 expression in non-alcoholic fatty liver and steatohepatitis. Hepatogastroenterology 58, 2077–2080.
307. Meakin PJ, Chowdhry S, Sharma RS, Ashford FB, Walsh SV, McCrimmon RJ, Dinkova-Kostova AT, Dillon JF, Hayes JD and Ashford ML (2014) Susceptibility of Nrf2-null mice to steatohepatitis and cirrhosis upon consumption of a high-fat diet is associated with oxidative stress, perturbation of the unfolded protein response, and disturbance in the expression of metabolic enzymes but not with insulin resistance. Mol Cell Biol 34, 3305–3320.
308. Lee LY, Köhler UA, Zhang L, Roenneburg D, Werner S, Johnson JA and Foley DP (2014) Activation of the Nrf2-ARE pathway in hepatocytes protects against steatosis in nutritionally induced non-alcoholic steatohepatitis in mice. Toxicol Sci 142, 361–374.
309. Sugimoto H, Okada K, Shoda J, Warabi E, Ishige K, Ueda T, Taguchi K, Yanagawa T, Nakahara A, Hyodo I et al. (2010) Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice. Am J Physiol Gastrointest Liver Physiol 298, G283–G294.
310. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, Tsujita T, Dillon JF, Ashford ML and Hayes JD (2010) Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48, 357–371.
311. Wang C, Cui Y, Li C, Zhang Y, Xu S, Li X, Li H and Zhang X (2013) Nrf2 deletion causes “benign” simple steatosis to develop into nonalcoholic steatohepatitis in mice fed a high-fat diet. Lipids Health Dis 12, 165.
312. Shimozono R, Asaoka Y, Yoshizawa Y, Aoki T, Noda H, Yamada M, Kaino M and Mochizuki H (2013) Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model. Mol Pharmacol 84, 62–70.
313. Xu Z, Chen L, Leung L, Yen TS, Lee C and Chan JY (2005) Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. Proc Natl Acad Sci USA 102, 4120–4125.
314. Geetha T, Zheng C, Vishwaprakash N, Broderick TL and Babu JR (2012) Sequestosome 1/p62, a scaffolding protein, is a newly identified partner of IRS-1 protein. J Biol Chem 287, 29672–29678.
315. Popineau L, Morzyglod L, Carré N, Caüzac M, Bossard P, Prip-Buus C, Lenoir V, Ragazzon B, Fauveau V, Robert L et al. (2016) A novel Grb14-mediated cross-talk between insulin and p62/Nrf2 pathways regulates liver lipogenesis and selective insulin resistance. Mol Cell Biol pii: MCB.00170-16.
316. Chen K, Zeng J, Xiao H, Huang C, Hu J, Yao W, Yu G, Xiao W, Xu H and Ye Z (2016) Regulation of glucose metabolism by p62/SQSTM1 through HIF1alpha. J Cell Sci 129, 817–830.
317. Zhang M, Zhang C, Zhang L, Yang Q, Zhou S, Wen Q and Wang J (2015) Nrf2 is a potential prognostic marker and promotes proliferation and invasion in human hepatocellular carcinoma. BMC Cancer 15, 531.
318. Shibata T and Aburatani H (2014) Exploration of liver cancer genomes. Nat Rev Gastroenterol Hepatol 11, 340–349.
319. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M and Zucman-Rossi J (2014) Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology 60, 1983–1992.
320. Zavattari P, Perra A, Menegon S, Kowalik MA, Petrelli A, Angioni MM, Follenzi A, Quagliata L, Ledda-Columbano GM and Terracciano L (2015) Nrf2, but not beta-catenin, mutation represents an early event in rat hepatocarcinogenesis. Hepatology 62, 851–862.
321. Puvirajesinghe TM, Bertucci F, Jain A, Scerbo P, Belotti E, Audebert S, Sebbagh M, Lopez M, Brech A, Finetti P et al. (2016) Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. Nat Commun 7, 10318.
322. Cai-McRae X, Zhong H and Karantza V (2015) Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways. Oncogene 34, 2968–2977.
323. Zatloukal K, French SW, Stumptner C, Strnad P, Harada M, Toivola DM, Cadrin M and Omary MB (2007) From Mallory to Mallory-Denk bodies: what, how and why? Exp Cell Res 313, 2033–2049.
324. Hua F, Li K, Yu JJ, Lv XX, Yan J, Zhang XW, Sun W, Lin H, Shang S, Wang F et al. (2015) TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/proteasomal degradations. Nat Commun 6, 7951.
325. Wu Y, Li Y, Zhang H, Huang Y, Zhao P, Tang Y, Qiu X, Ying Y, Li W, Ni S et al. (2015) Autophagy and mTORC1 regulate the stochastic phase of somatic cell reprogramming. Nat Cell Biol 17, 715–725.
326. Hawkins KE, Joy S, Delhove JM, Kotiadis VN, Fernandez E, Fitzpatrick LM, Whiteford JR, King PJ, Bolanos JP, Duchen MR et al. (2016) NRF2 orchestrates the metabolic shift during induced pluripotent stem cell reprogramming. Cell Rep 14, 1883–1891.
327. Kowalik MA, Guzzo G, Morandi A, Perra A, Menegon S, Masgras I, Trevisan E, Angioni MM, Fornari F, Quagliata L et al. (2016) Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. Oncotarget, doi: 10.18632/oncotarget.8632.
328. Yu Y, Liang D, Tian Q, Chen X, Jiang B, Chou BK, Hu P, Cheng L, Gao P, Li J et al. (2014) Stimulation of somatic cell reprogramming by ERas-Akt-FoxO1 signaling axis. Stem Cells 32, 349–363.
329. Wang Y, Zhang N, Zhang L, Li R, Fu W, Ma K, Li X, Wang L, Wang J, Zhang H et al. (2016) Autophagy regulates chromatin ubiquitination in DNA damage response through elimination of SQSTM1/p62. Mol Cell 63, 34–48.
330. Hewitt G, Carroll B, Sarallah R, Correia-Melo C, Ogrodnik M, Nelson G, Otten EG, Manni D, Antrobus R, Morgan BA et al. (2016) SQSTM1/p62 mediates crosstalk between autophagy and the UPS in DNA repair. Autophagy, PMID: 27391408.